Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts.

Rice L, Samedi VG, Medrano TA, Sweeney CA, Baker HV, Stenstrom A, Furman J, Shiverick KT.

Prostate. 2002 Aug 1;52(3):201-12.

PMID:
12111696
2.

Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells.

Handayani R, Rice L, Cui Y, Medrano TA, Samedi VG, Baker HV, Szabo NJ, Shiverick KT.

J Nutr. 2006 Jan;136(1):75-82.

3.

A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.

Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE.

Clin Cancer Res. 2004 Aug 1;10(15):5282-92.

4.

Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis.

Zhou JR, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK.

Cancer Res. 1998 Nov 15;58(22):5231-8.

5.

Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.

Liu CM, Lo YC, Tai MH, Wu BN, Wu WJ, Chou YH, Chai CY, Huang CH, Chen IJ.

Prostate. 2009 May 1;69(6):610-23. doi: 10.1002/pros.20919.

PMID:
19143029
7.

Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition.

Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D, Nelson PS.

J Natl Cancer Inst. 2002 Nov 6;94(21):1641-7.

8.
9.

Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene.

Cao F, Jin TY, Zhou YF.

Biomed Environ Sci. 2006 Feb;19(1):35-41.

PMID:
16673816
10.

Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice.

Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK.

J Nutr. 1999 Sep;129(9):1628-35.

11.

Silvestrol regulates G2/M checkpoint genes independent of p53 activity.

Mi Q, Kim S, Hwang BY, Su BN, Chai H, Arbieva ZH, Kinghorn AD, Swanson SM.

Anticancer Res. 2006 Sep-Oct;26(5A):3349-56.

12.
13.

Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model.

Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR.

Cancer Res. 2002 Jun 1;62(11):3298-307.

14.

Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.

Siu SW, Lau KW, Tam PC, Shiu SY.

Prostate. 2002 Jul 1;52(2):106-22. Erratum in: Prostate 2002 Aug 1;52(3):252.

PMID:
12111702
15.
16.

Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo.

Srivastava SK, Xiao D, Lew KL, Hershberger P, Kokkinakis DM, Johnson CS, Trump DL, Singh SV.

Carcinogenesis. 2003 Oct;24(10):1665-70.

17.

Anti-prostate cancer activity of a beta-carboline alkaloid enriched extract from Rauwolfia vomitoria.

Bemis DL, Capodice JL, Gorroochurn P, Katz AE, Buttyan R.

Int J Oncol. 2006 Nov;29(5):1065-73.

PMID:
17016636
19.

Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.

Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D.

Prostate. 2004 May 15;59(3):243-51.

PMID:
15042599
20.

Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo.

Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J, Sarkar FH, Hillman GG.

Cancer Res. 2007 Mar 1;67(5):2141-9.

Items per page

Supplemental Content

Support Center